BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 10731940)

  • 81. Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95.
    Hinze L; Möricke A; Zimmermann M; Junk S; Cario G; Dagdan E; Kratz CP; Conter V; Schrappe M; Stanulla M
    Leukemia; 2017 Aug; 31(8):1840-1842. PubMed ID: 28529312
    [No Abstract]   [Full Text] [Related]  

  • 82. Aggressive chemotherapy for acute leukemia relapsed after bone marrow transplantation: a second chance?
    Sica S; Di Mario A; Pagano L; Etuk B; Salutari P; Leone G
    Acta Haematol; 1992; 87(4):173-5. PubMed ID: 1519431
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Results of the treatment of childhood acute lymphoblastic leukemia according to the Berlin-Moscow-91 protocol in 1991-2000].
    Miakova NV; Hartmann R; Rudneva AE; Trubina NM; Fechina LG; Timakov AM; Shamardina AV; Lebedev VV; Varfolomeeva SR; Dudkin SD; Dyshlevaia ZM; Timofeeva VN; Rumiantsev AG; Henze H; Karachunskiĭ AI
    Vopr Onkol; 2002; 48(3):340-6. PubMed ID: 12455359
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [The influence of age, gender and modifications of therapeutic protocols on physical development of children and adolescents after completion of therapy for acute lymphoblastic leukemia].
    Krawczuk-Rybak M; Kaliszewski J; Kitszel A
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2003; 9(1):41-7. PubMed ID: 12831637
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
    Lauten M; Möricke A; Beier R; Zimmermann M; Stanulla M; Meissner B; Odenwald E; Attarbaschi A; Niemeyer C; Niggli F; Riehm H; Schrappe M
    Haematologica; 2012 Jul; 97(7):1048-56. PubMed ID: 22271901
    [TBL] [Abstract][Full Text] [Related]  

  • 86. High-dose chemotherapy and autologous peripheral blood stem cell transplantation with BCVAC regimen followed by maintenance chemotherapy for children with very high risk acute lymphoblastic leukemia.
    Hong CR; Kang HJ; Park KD; Shin HY; Ahn HS
    Int J Hematol; 2018 Mar; 107(3):355-362. PubMed ID: 29052026
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia.
    Panzer-Grümayer ER; Schneider M; Panzer S; Fasching K; Gadner H
    Blood; 2000 Feb; 95(3):790-4. PubMed ID: 10648387
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90.
    Neth O; Seidemann K; Jansen P; Mann G; Tiemann M; Ludwig WD; Riehm H; Reiter A
    Med Pediatr Oncol; 2000 Jul; 35(1):20-7. PubMed ID: 10881003
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Modified BFM-90 regimen greatly improves treatment outcomes of chinese childhood and adolescent lymphoblastic lymphoma].
    Sun XF; Zhen ZJ; Liu DG; Xia ZJ; Huang HQ; Zhang L; Zhou ZM; Li YH; Xia Y; Ling JY; Guan ZZ
    Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):58-61. PubMed ID: 17575697
    [TBL] [Abstract][Full Text] [Related]  

  • 90. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
    Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
    Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group.
    Henze G; Fengler R; Hartmann R; Kornhuber B; Janka-Schaub G; Niethammer D; Riehm H
    Blood; 1991 Sep; 78(5):1166-72. PubMed ID: 1878583
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study.
    Hunault-Berger M; Milpied N; Bernard M; Jouet JP; Delain M; Desablens B; Sadoun A; Guilhot F; Casassus P; Ifrah N
    Leukemia; 2001 Jun; 15(6):898-902. PubMed ID: 11417474
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The dose related effect of steroids on blast reduction rate and event free survival in children with acute lymphoblastic leukemia.
    Yetgin S; Cetin M
    Leuk Lymphoma; 2003 Mar; 44(3):489-95. PubMed ID: 12688320
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Superior prognosis in combined compared to isolated bone marrow relapses in salvage therapy of childhood acute lymphoblastic leukemia.
    Bührer C; Hartmann R; Fengler R; Dopfer R; Gadner H; Gerein V; Göbel U; Reiter A; Ritter J; Henze G
    Med Pediatr Oncol; 1993; 21(7):470-6. PubMed ID: 8341213
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Second induction in pediatric patients with recurrent acute lymphoid leukemia using DFCI-ALL protocols.
    Dalle JH; Moghrabi A; Rousseau P; Leclerc JM; Barrette S; Bernstein ML; Champagne J; David M; Demers J; Duval M; Hume H; Meyer P; Champagne MA
    J Pediatr Hematol Oncol; 2005 Feb; 27(2):73-9. PubMed ID: 15701980
    [TBL] [Abstract][Full Text] [Related]  

  • 96. ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse.
    Giona F; Testi AM; Rondelli R; Amadori S; Arcese W; Meloni G; Moleti ML; Ceci A; Pillon M; Madon E; Comis M; Pession A; Mandelli F
    Br J Haematol; 1997 Dec; 99(3):671-7. PubMed ID: 9401083
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Hypofractionated moderate dose radiation, intrathecal chemotherapy, and repetitive reinduction/reconsolidation systemic therapy for central nervous system relapse of acute lymphoblastic leukemia in children.
    Belasco JB; Goldwein JW; Simms S; Griffin G; D'Angio G; Lange B
    Med Pediatr Oncol; 2000 Feb; 34(2):125-31. PubMed ID: 10657874
    [TBL] [Abstract][Full Text] [Related]  

  • 98. [Reults of treatment with protocols BFM 90 and BFM 95].
    Sakić M; Berbić-Fazlagić J
    Med Arh; 2006; 60(6):369-72. PubMed ID: 17297851
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia.
    Brisco J; Hughes E; Neoh SH; Sykes PJ; Bradstock K; Enno A; Szer J; McCaul K; Morley AA
    Blood; 1996 Jun; 87(12):5251-6. PubMed ID: 8652840
    [TBL] [Abstract][Full Text] [Related]  

  • 100. [Acute lymphoblastic leukemia in childhood: the COALL studies].
    Janka GE; Winkler K; Jürgens H; Göbel U; Gutjahr P; Spaar HJ
    Klin Padiatr; 1986; 198(3):171-7. PubMed ID: 3523023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.